An Open-Label, Randomized, Phase 2 Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma

Trial Profile

An Open-Label, Randomized, Phase 2 Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Jul 2017

At a glance

  • Drugs Nivolumab (Primary) ; Ipilimumab
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Acronyms CheckMate-064
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 26 Jul 2017 Planned End Date changed from 1 Apr 2018 to 19 Apr 2018.
    • 06 Jun 2017 Results assessing the association between baseline Biomarkers and clinical response, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 01 Feb 2017 Planned End Date changed from 1 Apr 2017 to 1 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top